The introduction of pharmaceutical product patents in India: "heartless exploitation of the poor and suffering"?
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Cambridge, Mass.
1998
|
| Schriftenreihe: | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series
6366 |
| Schlagwörter: | |
| Links: | http://papers.nber.org/papers/w6366.pdf |
| Abstract: | The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost 50 developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business interest in the West urged them to consider the benefits such protection might bring both in terms of focusing more research on tropical diseases and encouraging greater domestic and foreign investment in local research activities. This paper discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals. Using India as an example, it then brings together information gathered from both published sources and personal interviews to examine the potential magnitude of these effects. While not arriving at a conclusive answer to the question posed in the title, there are some suggestions about the way events might unfold as the policy is implemented. |
| Umfang: | 53 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV011861919 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t| | ||
| 008 | 980331s1998 xxud||| |||| 00||| engod | ||
| 035 | |a (OCoLC)38524150 | ||
| 035 | |a (DE-599)BVBBV011861919 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-19 |a DE-521 | ||
| 050 | 0 | |a HB1 | |
| 100 | 1 | |a Lanjouw, Jean O. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a The introduction of pharmaceutical product patents in India |b "heartless exploitation of the poor and suffering"? |c Jean O. Lanjouw |
| 264 | 1 | |a Cambridge, Mass. |c 1998 | |
| 300 | |a 53 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 6366 | |
| 520 | 3 | |a The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost 50 developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business interest in the West urged them to consider the benefits such protection might bring both in terms of focusing more research on tropical diseases and encouraging greater domestic and foreign investment in local research activities. This paper discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals. Using India as an example, it then brings together information gathered from both published sources and personal interviews to examine the potential magnitude of these effects. While not arriving at a conclusive answer to the question posed in the title, there are some suggestions about the way events might unfold as the policy is implemented. | |
| 650 | 7 | |a Brevets d'invention - Aspect économique - Inde |2 ram | |
| 650 | 7 | |a Industrie pharmaceutique - Inde |2 ram | |
| 650 | 7 | |a Médicaments - Prix - Inde - Modèles économétriques |2 ram | |
| 650 | 7 | |a Médicaments - Recherche - Aspect économique - Inde |2 ram | |
| 650 | 7 | |a Politique pharmaceutique - Aspect économique - Inde |2 ram | |
| 650 | 4 | |a Ökonometrisches Modell | |
| 650 | 4 | |a Drugs |x Prices |z India |x Econometric models | |
| 650 | 4 | |a Drugs |x Research |x Economic aspects |z India | |
| 650 | 4 | |a Patents |x Economic aspects |z India | |
| 650 | 4 | |a Pharmaceutical industry |z India | |
| 650 | 4 | |a Pharmaceutical policy |x Economic aspects |z India | |
| 651 | 4 | |a Indien | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |
| 830 | 0 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 6366 |w (DE-604)BV002801238 |9 6366 | |
| 856 | 4 | 1 | |u http://papers.nber.org/papers/w6366.pdf |z kostenfrei |3 Volltext |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-008013427 | |
Datensatz im Suchindex
| _version_ | 1818954313040396288 |
|---|---|
| any_adam_object | |
| author | Lanjouw, Jean O. |
| author_facet | Lanjouw, Jean O. |
| author_role | aut |
| author_sort | Lanjouw, Jean O. |
| author_variant | j o l jo jol |
| building | Verbundindex |
| bvnumber | BV011861919 |
| callnumber-first | H - Social Science |
| callnumber-label | HB1 |
| callnumber-raw | HB1 |
| callnumber-search | HB1 |
| callnumber-sort | HB 11 |
| callnumber-subject | HB - Economic Theory and Demography |
| ctrlnum | (OCoLC)38524150 (DE-599)BVBBV011861919 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03060nam a2200469 cb4500</leader><controlfield tag="001">BV011861919</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">980331s1998 xxud||| |||| 00||| engod</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)38524150</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011861919</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-521</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB1</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lanjouw, Jean O.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The introduction of pharmaceutical product patents in India</subfield><subfield code="b">"heartless exploitation of the poor and suffering"?</subfield><subfield code="c">Jean O. Lanjouw</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">53 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">6366</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost 50 developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business interest in the West urged them to consider the benefits such protection might bring both in terms of focusing more research on tropical diseases and encouraging greater domestic and foreign investment in local research activities. This paper discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals. Using India as an example, it then brings together information gathered from both published sources and personal interviews to examine the potential magnitude of these effects. While not arriving at a conclusive answer to the question posed in the title, there are some suggestions about the way events might unfold as the policy is implemented.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brevets d'invention - Aspect économique - Inde</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Industrie pharmaceutique - Inde</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Médicaments - Prix - Inde - Modèles économétriques</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Médicaments - Recherche - Aspect économique - Inde</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Politique pharmaceutique - Aspect économique - Inde</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ökonometrisches Modell</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Prices</subfield><subfield code="z">India</subfield><subfield code="x">Econometric models</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Research</subfield><subfield code="x">Economic aspects</subfield><subfield code="z">India</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patents</subfield><subfield code="x">Economic aspects</subfield><subfield code="z">India</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">India</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="x">Economic aspects</subfield><subfield code="z">India</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">Indien</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">6366</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">6366</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://papers.nber.org/papers/w6366.pdf</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008013427</subfield></datafield></record></collection> |
| geographic | Indien |
| geographic_facet | Indien |
| id | DE-604.BV011861919 |
| illustrated | Illustrated |
| indexdate | 2024-12-20T10:20:11Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008013427 |
| oclc_num | 38524150 |
| open_access_boolean | 1 |
| owner | DE-19 DE-BY-UBM DE-521 |
| owner_facet | DE-19 DE-BY-UBM DE-521 |
| physical | 53 S. graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| record_format | marc |
| series | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| series2 | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| spelling | Lanjouw, Jean O. Verfasser aut The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? Jean O. Lanjouw Cambridge, Mass. 1998 53 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 6366 The decision to require that countries grant product patents for pharmaceutical innovations as a condition of membership in the World Trade Organization was very contentious. Almost 50 developing countries were not granting patent monopolies for drugs during the period the Uruguay round of GATT was being debated and these countries fiercely resisted the inclusion of this requirement, claiming that vastly higher drug prices would be associated with such patents. On the other side, business interest in the West urged them to consider the benefits such protection might bring both in terms of focusing more research on tropical diseases and encouraging greater domestic and foreign investment in local research activities. This paper discusses the various theoretical implications for a developing country of introducing product patents for pharmaceuticals. Using India as an example, it then brings together information gathered from both published sources and personal interviews to examine the potential magnitude of these effects. While not arriving at a conclusive answer to the question posed in the title, there are some suggestions about the way events might unfold as the policy is implemented. Brevets d'invention - Aspect économique - Inde ram Industrie pharmaceutique - Inde ram Médicaments - Prix - Inde - Modèles économétriques ram Médicaments - Recherche - Aspect économique - Inde ram Politique pharmaceutique - Aspect économique - Inde ram Ökonometrisches Modell Drugs Prices India Econometric models Drugs Research Economic aspects India Patents Economic aspects India Pharmaceutical industry India Pharmaceutical policy Economic aspects India Indien Erscheint auch als Online-Ausgabe National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 6366 (DE-604)BV002801238 6366 http://papers.nber.org/papers/w6366.pdf kostenfrei Volltext |
| spellingShingle | Lanjouw, Jean O. The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series Brevets d'invention - Aspect économique - Inde ram Industrie pharmaceutique - Inde ram Médicaments - Prix - Inde - Modèles économétriques ram Médicaments - Recherche - Aspect économique - Inde ram Politique pharmaceutique - Aspect économique - Inde ram Ökonometrisches Modell Drugs Prices India Econometric models Drugs Research Economic aspects India Patents Economic aspects India Pharmaceutical industry India Pharmaceutical policy Economic aspects India |
| title | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? |
| title_auth | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? |
| title_exact_search | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? |
| title_full | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? Jean O. Lanjouw |
| title_fullStr | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? Jean O. Lanjouw |
| title_full_unstemmed | The introduction of pharmaceutical product patents in India "heartless exploitation of the poor and suffering"? Jean O. Lanjouw |
| title_short | The introduction of pharmaceutical product patents in India |
| title_sort | the introduction of pharmaceutical product patents in india heartless exploitation of the poor and suffering |
| title_sub | "heartless exploitation of the poor and suffering"? |
| topic | Brevets d'invention - Aspect économique - Inde ram Industrie pharmaceutique - Inde ram Médicaments - Prix - Inde - Modèles économétriques ram Médicaments - Recherche - Aspect économique - Inde ram Politique pharmaceutique - Aspect économique - Inde ram Ökonometrisches Modell Drugs Prices India Econometric models Drugs Research Economic aspects India Patents Economic aspects India Pharmaceutical industry India Pharmaceutical policy Economic aspects India |
| topic_facet | Brevets d'invention - Aspect économique - Inde Industrie pharmaceutique - Inde Médicaments - Prix - Inde - Modèles économétriques Médicaments - Recherche - Aspect économique - Inde Politique pharmaceutique - Aspect économique - Inde Ökonometrisches Modell Drugs Prices India Econometric models Drugs Research Economic aspects India Patents Economic aspects India Pharmaceutical industry India Pharmaceutical policy Economic aspects India Indien |
| url | http://papers.nber.org/papers/w6366.pdf |
| volume_link | (DE-604)BV002801238 |
| work_keys_str_mv | AT lanjouwjeano theintroductionofpharmaceuticalproductpatentsinindiaheartlessexploitationofthepoorandsuffering |